Spots Global Cancer Trial Database for rifampin
Every month we try and update this database with for rifampin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | NCT02608034 | Metastatic Mela... | Itraconazole Rifampin Vemurafenib | 18 Years - | Genentech, Inc. | |
| Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | NCT01844583 | Solid Tumors Lymphoma | Alisertib Esomeprazole Rifampin | 18 Years - | Takeda | |
| Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | NCT06348290 | Solid Tumor, Ad... | JMKX001899 Itraconazole Midazolam Rifampin dextromethorpha... Rosuvastatin digoxin | 18 Years - 45 Years | Jemincare | |
| A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer | NCT00534807 | Cancer | Vinflunine Rifampin | 18 Years - | Bristol-Myers Squibb | |
| Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer | NCT00207090 | Advanced Solid ... Neoplasms | ixabepilone Rifampin | 18 Years - | R-Pharm | |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324323 | Hematologic Mal... Malignant Lymph... | Romidepsin Rifampin | 18 Years - | Celgene | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | NCT06348290 | Solid Tumor, Ad... | JMKX001899 Itraconazole Midazolam Rifampin dextromethorpha... Rosuvastatin digoxin | 18 Years - 45 Years | Jemincare | |
| Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer | NCT00207090 | Advanced Solid ... Neoplasms | ixabepilone Rifampin | 18 Years - | R-Pharm | |
| Effect of Rifampin on the Pharmacokinetics of BAY73-4506 | NCT01322438 | Neoplasms | Regorafenib (BA... | 18 Years - 45 Years | Bayer | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | NCT01954043 | Cancer | Dabrafenib 150 ... Rabeprazole 40 ... Rifampin 600 mg... | 18 Years - | GlaxoSmithKline | |
| Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma | NCT01454076 | Nonhematologic ... Lymphoma | Ixazomib 2.5 mg Ixazomib 4 mg C... Ixazomib 4 mg C... Ketoconazole Rifampin Clarithromycin Ixazomib 4 mg C... | 18 Years - | Takeda | |
| A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | NCT01954043 | Cancer | Dabrafenib 150 ... Rabeprazole 40 ... Rifampin 600 mg... | 18 Years - | GlaxoSmithKline | |
| Effect of Rifampin on the Pharmacokinetics of BAY73-4506 | NCT01322438 | Neoplasms | Regorafenib (BA... | 18 Years - 45 Years | Bayer | |
| COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients | NCT02253420 | Medical Oncolog... | Copanlisib (BAY... Itraconazole Rifampin Copanlisib (BAY... | 18 Years - | Bayer | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors | NCT04312282 | Advanced Solid ... | Tesetaxel Tesetaxel Itraconazole Rifampin | 18 Years - | Odonate Therapeutics, Inc. | |
| A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) | NCT01765543 | Malignant Melan... | Rifampin Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors | NCT03077607 | Advanced Solid ... | Talazoparib Itraconazole Rifampin | 18 Years - | Pfizer | |
| A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects | NCT03346837 | Malignancies Mu... | BMS-986205 Itraconazole Rifampin | 18 Years - 50 Years | Bristol-Myers Squibb | |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors | NCT01218620 | Adult Solid Neo... | Gamma-Secretase... Ketoconazole Rifampin Midazolam Hydro... Omeprazole Tolbutamide Dextromethorpha... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | NCT03994211 | Solid Tumor | pamiparib 60 mg pamiparib 20 mg itraconazole rifampin pamiparib | 18 Years - | BeiGene | |
| A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer | NCT00585195 | Non-Small Cell ... Non-Small Cell ... Non-Small Cell ... Systemic Anapla... Advanced Malign... | PF-02341066 Rifampin Itraconazole | 18 Years - | Pfizer | |
| A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer | NCT00585195 | Non-Small Cell ... Non-Small Cell ... Non-Small Cell ... Systemic Anapla... Advanced Malign... | PF-02341066 Rifampin Itraconazole | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
